[Form 4] Labcorp Holdings Inc. Insider Trading Activity

Rhea-AI Filing Summary

Adam H. Schechter, President & CEO and Director of Labcorp Holdings Inc. (LH), reported a sale of company common stock on 08/11/2025. The Form 4 discloses that 5,643 shares were disposed of at a reported price of $266.78 per share pursuant to a plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The filing was executed by an attorney-in-fact on 08/13/2025.

After the reported transaction Schechter beneficially owns 93,319 shares directly. No derivative transactions are reported on this Form 4. The disclosure identifies the transaction code as an S-sale under the stated 10b5-1 plan.

Positive

• Transaction disclosed under Rule 10b5-1, indicating the sale was executed pursuant to a documented trading plan as stated in the filing.
• Timely Form 4 reporting with signature by an attorney-in-fact, providing clear disclosure of the insider transaction and resulting ownership.

Negative

• Insider disposed of 5,643 shares, reducing direct beneficial holdings to 93,319 shares as reported.
• No additional context provided in the filing about the origin or intent of the 10b5-1 plan beyond the single explanatory line.

Insights

Corporate Governance Expert

TL;DR: Routine insider sale disclosed under a 10b5-1 plan; governance disclosure appears complete and timely.

The Form 4 shows a direct sale of 5,643 common shares by Adam H. Schechter on 08/11/2025 at $266.78 per share and cites a Rule 10b5-1 trading plan in the explanation. From a governance perspective, reporting an insider sale executed pursuant to a documented 10b5-1 plan provides transparency on the transaction framework and reduces questions about ad hoc timing. The form also records the reporting signature by an attorney-in-fact, indicating procedural completion of the filing.

Securities Analyst

TL;DR: Insider sale is disclosed but not large enough on its face to be materially disruptive to share count.

The filing documents a single non-derivative disposition of 5,643 shares by the companys President & CEO, leaving a reported direct beneficial ownership of 93,319 shares. No derivative holdings were reported in Table II. For investors, the key facts are the number of shares sold, the $266.78 reported price, and that the sale was made under a Rule 10b5-1 plan; these details allow market participants to assess size and timing without additional context from the filing itself.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schechter Adam H

(Last) (First) (Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON NC 27215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2025		S(1)		5,643	D	$266.78	93,319	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

	/s/ Sandra D. van der Vaart, Attorney-in-Fact for Adam H. Schechter	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Adam H. Schechter report on the Labcorp (LH) Form 4?

The Form 4 reports a sale of 5,643 shares of Labcorp common stock on 08/11/2025 at a reported price of $266.78 per share under a Rule 10b5-1 plan.

How many Labcorp (LH) shares does Adam Schechter own after the transaction?

Following the reported transaction, Schechter is shown as beneficially owning 93,319 shares directly.

Was the sale by Adam Schechter part of a pre-arranged trading plan?

Yes. The filing explanation states the transaction was made pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.

Are there any derivative transactions reported in this Form 4 for Labcorp (LH)?

No. Table II (derivative securities) in the provided Form 4 is empty, indicating no derivative transactions were reported.

Who signed the Form 4 for Adam H. Schechter?

The Form 4 was signed by Sandra D. van der Vaart, Attorney-in-Fact for Adam H. Schechter on 08/13/2025.